Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma 10 September 2021
Press Release NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company”... Read more